CCM
BRNS

CAAS Capital Management’s Barinthus Biotherapeutics BRNS Stock Holding History

CAAS Capital Management’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,251
Closed -$161K – 879
2021
Q3 		$161K Sell
10,251
-39,749
-79% -$604K ﹤0.01% 754
2021
Q2 		$839K Buy
+50,000
New +$740K 0.01% 627

Other funds holding BRNS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

CAAS Capital Management's BRNS Position: Q4 2021 in Review

CAAS Capital Management sold out of Barinthus Biotherapeutics (BRNS) in Q4 2021, closing a stake of 10,251 shares — an estimated $161K sold.

CAAS Capital Management first reported a position in BRNS in Q2 2021 and held it in 2 quarters. The position peaked at $839K in Q2 2021. 15 funds tracked by Wall St. Rank hold BRNS as of Q4 2021.

  • CAAS Capital Management reported no remaining Barinthus Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 10,251 Barinthus Biotherapeutics shares in Q4 2021, an estimated $161K.
  • CAAS Capital Management first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • CAAS Capital Management's Barinthus Biotherapeutics position peaked at $839K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.